"The nurses taking the blood samples preferred this method over the DBS-method, Mitra doesn't need a ‘drying period,’ because the packaging is designed to not touch anything. Therefore, the Mitra stick can be put away immediately. DBS cards need to dry, which is in tropical area in not that fast. Having a couple of hundred cards standing around for drying is inconvenient, especially if working space is limited in the field and the DBS are exposed to sand, dirt, and wind.”
– Dr. Jennifer Keiser, PhD | Swiss Tropical Public Health Institute, Switzerland
In the US, use of the Mitra device is limited to research and non-diagnostic applications. In many countries outside the US, the Mitra device can be used as a sample collection device for clinical diagnostic applications, as referenced in this content.
The Clamshell format facilitates simple remote specimen sampling. This means easier participant recruitment and lower logistical costs.
Get accurate, reliable profiles with smaller samples from fewer rodents. Sample the same animal at multiple time points for improved data quality.
Want to practice logistics prior to a full scale deployment? The Clamshell format provides an economical way to do it.
When grants and budgets are limited, the Clamshell format provides an inexpensive way to collect samples from large global groups.
|
|
|
10 µL | 20 µL | 30 µL |
Contact Us
Trajan Scientific Americas Inc.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Mitra® devices are intended as a specimen collector and for the storage and transport of blood. They are CE-IVD in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada and Ukraine.
In the USA, Mitra devices are supplied as a Research-Use Only (RUO) product, to assist in method development, other research-related and non-diagnostic activities. Mitra has not been validated for use with any diagnostic testing. The suitability of Mitra for any analytical application must be evaluated and validated by the laboratory or research institute in a manner consistent with local regulatory requirements.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use.
Mitra®, VAMS® & hemaPEN® are registered trademarks owned by entities in the Trajan Group.
Copyright © 2022. All rights reserved.